Brett Nowlan, MD
Cardiovascular Disease · Bloomfield, CTNPI 1861688772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $684,887 of the $797,665 with a category attached, or 85.9%. It is spread thinly across 37 manufacturers, the largest accounting for just 20.8%. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,284 payments — averaging $621.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$166K
- Novo Nordisk$138K
- Esperion Therapeutics, Inc.$126K
- Amarin Pharma, Inc.$115K
- Sanofi-aventis U.S. LLC$84K
- Boehringer Ingelheim$77K
- plus $92K from 31 others
What the payments were for
- Consulting fees$4,0301%
- Speaking & faculty fees$684,88786%
- Travel & lodging$78,67110%
- Food & beverage$30,0334%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 224 | $165,884 |
| Novo Nordisk | 87 | $137,643 |
| Esperion Therapeutics, Inc. | 128 | $125,803 |
| Amarin Pharma, Inc. | 167 | $115,105 |
| Sanofi-aventis U.S. LLC | 97 | $84,432 |
| Boehringer Ingelheim | 132 | $76,678 |
| Lilly USA, LLC | 65 | $65,308 |
| Regeneron Healthcare Solutions, Inc. | 37 | $15,968 |
| Johnson & Johnson | 69 | $4,907 |
| Novartis | 40 | $895 |
| Pfizer | 41 | $690 |
| AstraZeneca | 34 | $558 |
| Heartflow, Inc. | 17 | $535 |
| Abbott | 8 | $460 |
| Boston Scientific | 10 | $417 |
| E.r. Squibb & Sons, L.L.C. | 29 | $394 |
| Bayer | 14 | $325 |
| Alnylam Pharmaceuticals Inc. | 14 | $306 |
| Kowa Pharmaceuticals America, Inc. | 20 | $254 |
| Actelion Pharmaceuticals US, Inc. | 10 | $224 |
| Scpharmaceuticals Inc. | 7 | $123 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $116 |
| Merck | 5 | $85 |
| Agepha Pharma FZ LLC | 2 | $82 |
| Lexicon Pharmaceuticals, Inc. | 3 | $61 |
| Ionis Pharmaceuticals, Inc. | 2 | $57 |
| Impulse Dynamics (USA) Inc. | 3 | $55 |
| Preventice Services, LLC | 1 | $51 |
| Sanofi | 2 | $43 |
| Bridgebio Pharma, Inc. | 2 | $33 |
| Abiomed | 1 | $32 |
| Vifor Pharma, Inc. | 2 | $31 |
| Chiesi USA, Inc. | 1 | $30 |
| Irhythm Technologies, Inc. | 1 | $28 |
| Bardy Diagnostics, Inc. | 4 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Medicomp Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$163,309
- JARDIANCE$135,238
- NEXLIZET$124,289
- NEXLETOL$124,289
- Vascepa$112,723
- PRALUENT$94,797
- Wegovy$71,637
- XARELTO$4,050
- DISEASE STATE$2,530
- CARDIOMEMS$290
- FFRct$251
- Ozempic$244
- WATCHMAN Access System$204
How this compares
$797,665 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 334 | $400,347 |
| JardianceEmpagliflozin | 85 | $139,521 |
| EliquisApixaban | 95 | $139,234 |
| VascepaIcosapent Ethyl | 140 | $133,266 |
| OzempicSemaglutide | 109 | $124,602 |
| Praluent PenAlirocumab | 113 | $124,185 |
| NexlizetBempedoic Acid/Ezetimibe | 45 | $37,683 |
| MounjaroTirzepatide | 29 | $29,774 |
| EntrestoSacubitril/Valsartan | 13 | $25,200 |
| XareltoRivaroxaban | 14 | $16,786 |
| Icosapent Ethyl | 43 | $13,290 |
| NexletolBempedoic Acid | 13 | $12,317 |
| Ezetimibe | 127 | $2,294 |
| Rosuvastatin Calcium | 138 | $2,079 |
| Colchicine | 38 | $1,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $76,678 | $139,52185 claims |
| PfizerEliquis | $690 | $139,23495 claims |
| Novo NordiskOzempic | $137,643 | $124,602109 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $125,803 | $50,00058 claims |
| Lilly USA, LLCMounjaro | $65,308 | $29,77429 claims |
| NovartisEntresto | $895 | $25,20013 claims |
| Johnson & JohnsonXarelto | $4,907 | $16,78614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Bloomfield
- Ronald BloomBloomfield$18K
- Tracy PatelBloomfield$10K
- Vincent RomanoBloomfield$10K
- Nihar DesaiNew Haven$1.4M
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.